CLASS I Device recall · Reported 26 Jul 2017 · FDA Enforcement Report

3D Revascularization Device It is indicated for used recalled

Penumbra is recalling Penumbra 3D Revascularization Device It is indicated for used in the revascularization of, distributed nationwide in the US. The recall was initiated on 9 Jun 2017 and the FDA has classified it as Class I.

Check your package

Lot, batch or date codesLots C00644, C00645, C00646, C00717
Quantity recalled155 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2702-2017
FDA event ID
77571
Recalling firm
Penumbra, Alameda, CA
Classification
Class I
Status
Terminated
Recall initiated
9 Jun 2017
FDA classified
20 Jul 2017
Reported
26 Jul 2017
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Lead & Heavy Metals

Timeline

9 Jun 2017Recall initiated by company
20 Jul 2017Classified by FDA+41 days
26 Jul 2017Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Penumbra has identified an issue in these four lots involving a raw material component of the delivery wire. This issue could result in breakage of the delivery wire, which could potentially lead to serious patient injury or death.

Lead and other heavy metals accumulate in the body. Children are most at risk; even low levels can affect development.

Product as listed by the FDA

Penumbra 3D Revascularization Device It is indicated for used in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral-M1 and M2 segments) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

Where it was distributed

Nationwide Distribution to the following states: AZ, CA, CO, FL, IN, MA, MI, MN, NV, NY, OH, OK, PA, SC, TN, TX, UT, VA, WV

Nationwide ArizonaCaliforniaColoradoFloridaIndianaMassachusettsMichiganMinnesotaNevadaNew YorkOhioOklahomaPennsylvaniaSouth CarolinaTennesseeTexasUtahVirginiaWest Virginia

Questions about this recall

Is 3D Revascularization Device It is indicated for used in the revascularization of patients recalled?

Yes. Penumbra recalled 3D Revascularization Device It is indicated for used in the revascularization of patients on 9 Jun 2017. The recall is Class I and its status is Terminated. Recall number Z-2702-2017.

Why was it recalled?

Penumbra has identified an issue in these four lots involving a raw material component of the delivery wire. This issue could result in breakage of the delivery wire, which could potentially lead to serious patient injury or death.

Which lots are affected?

Lots C00644, C00645, C00646, C00717

Where was it sold?

Nationwide Distribution to the following states: AZ, CA, CO, FL, IN, MA, MI, MN, NV, NY, OH, OK, PA, SC, TN, TX, UT, VA, WV

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class I mean?

Class I is the most serious FDA recall category: there is a reasonable probability that using the product will cause serious health consequences or death.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Penumbra

All 6

Other Heart & Vascular Devices recalls

All 6,199